Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences (IGMS) to Underweight from Equal Weight with a price target of $2, down from $12. The company announced discontinuation of its autoimmune programs, a 73% workforce reduction and plans to evaluate strategic alternatives, the analyst tells investors in a research note. The firm cites near-term uncertainty related to the future of IGM for the downgrade.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital
- IGM Biosciences reducing workforce by 73%, evaluating strategic alternatives
- IGM Biosciences halting further development of imvotamab and IGM-2644
- IGM Biosciences initiated with an Outperform at BMO Capital
- JPMorgan healthcare analysts hold an analyst/industry conference call